The DOI matches its Crossref record.
Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells
Abstract
The therapeutic efficacy of two bis(thiosemicarbazonato) copper complexes, glyoxalbis[N4-methylthiosemicarbazonato]Cu(II) [Cu(II)(gtsm)] and diacetylbis[N4-methylthiosemicarbazonato]Cu(II) [Cu(II)(atsm)], for the treatment of prostate cancer was assessed in cell culture and animal models. Distinctively, copper dissociates intracellularly from Cu(II)(gtsm) but is retained by Cu(II)(atsm). We further demonstrated that intracellular H2gtsm [reduced Cu(II)(gtsm)] continues to redistribute copper into a bioavailable (exchangeable) pool. Both Cu(II)(gtsm) and Cu(II)(atsm) selectively kill transformed (hyperplastic and carcinoma) prostate cell lines but, importantly, do not affect the viability of primary prostate epithelial cells. Increasing extracellular copper concentrations enhanced the therapeutic capacity of both Cu(II)(gtsm) and Cu(II)(atsm), and their ligands (H2gtsm and H2atsm) were toxic only toward cancerous prostate cells when combined with copper. Treatment of the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model with Cu(II)(gtsm) (2.5 mg/kg) significantly reduced prostate cancer burden (∼70%) and severity (grade), while treatment with Cu(II)(atsm) (30 mg/kg) was ineffective at the given dose. However, Cu(II)(gtsm) caused mild kidney toxicity in the mice, associated primarily with interstitial nephritis and luminal distention. Mechanistically, we demonstrated that Cu(II)(gtsm) inhibits proteasomal chymotrypsin-like activity, a feature further established as being common to copper-ionophores that increase intracellular bioavailable copper. We have demonstrated that increasing intracellular bioavailable copper can selectively kill cancerous prostate cells in vitro and in vivo and have revealed the potential for bis(thiosemicarbazone) copper complexes to be developed as therapeutics for prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Copper homeostasis and cuproptosis in health and disease
Chen, L., Min, J., & Wang, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01229-y · Cited by 1,493
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Self-citationCuproptosis: mechanisms and links with cancers
Xie, J., Yang, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01732-y · Cited by 801
Selective Targeting of Cancer Cells by Copper Ionophores: An Overview
Oliveri, V. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.841814 · Cited by 367
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metadata
- Authors
- Cater, M. A., Pearson, H. B., Wolyniec, K., Klaver, P., Bilandzic, M., Paterson, B. M., Bush, A. I., Humbert, P. O., La Fontaine, S., Donnelly, P. S., & Haupt, Y.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-05-24
- Volume
- 8
- Issue
- 7
- Pages
- 1621-1631
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2019523348
- Cited by
- 165
- References
- 0
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells. https://app.cochat.ai/papers/10.1021/cb400198p
- The paper
- Cater, M. A., Pearson, H. B., Wolyniec, K., Klaver, P., Bilandzic, M., Paterson, B. M., Bush, A. I., Humbert, P. O., La Fontaine, S., Donnelly, P. S., & Haupt, Y. (2013). Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells. ACS Chemical Biology. https://doi.org/10.1021/cb400198p
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.